Atypical case of cutaneous MCL mimics SPTCLMay 10, 2019Lymphoma & Plasma Cell DisordersNonmelanoma Skin Cancer
FDA opts not to ban textured breast implantsMay 3, 2019Lymphoma & Plasma Cell DisordersPreventive Care
CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myelomaMay 1, 2019Lymphoma & Plasma Cell Disorders
High-dose MTX-based chemo is well tolerated in older PCNSL patientsApril 24, 2019Lymphoma & Plasma Cell DisordersRare Diseases
Monitoring, early intervention key to CAR T safetyApril 24, 2019ImmunotherapyImmuno-oncologyLymphoma & Plasma Cell Disorders
Quality of life decrement with salvage ASCT is short-livedApril 23, 2019Lymphoma & Plasma Cell DisordersPatient & Survivor Care
RIT consolidation may be an option for unfit MCL patientsApril 17, 2019Lymphoma & Plasma Cell Disorders
Creating CAR T-cell therapies for T-cell malignanciesApril 16, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationImmunotherapyImmuno-oncologyRare Diseases
Dr. Louis Weiner: AACR presentations highlight new “transformative strategies”April 11, 2019Immuno-oncologyLymphoma & Plasma Cell Disorders
In situ vaccination produced responses in indolent NHLApril 8, 2019Lymphoma & Plasma Cell DisordersFollicular Lymphoma
DA-EPOCH-R appears more toxic than standard R-CHOP in DLBCLApril 5, 2019Lymphoma & Plasma Cell Disorders
Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphomaApril 5, 2019Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Early data support R-BAC for post-BTKi mantle cell lymphomaApril 5, 2019Lymphoma & Plasma Cell Disorders
